The prognostic and predictive value of serum CA19.9 in pancreatic cancer (Q34635104)

3 August 2017

title

The prognostic and predictive value of serum CA19.9 in pancreatic cancer (English)

1 reference

3 August 2017

1 reference

M Pajic

0 references

J L Humphris

1 reference

3 August 2017

D K Chang

1 reference

3 August 2017

A L Johns

1 reference

3 August 2017

C J Scarlett

1 reference

3 August 2017

M D Jones

1 reference

3 August 2017

E K Colvin

1 reference

3 August 2017

A Nagrial

1 reference

3 August 2017

V T Chin

1 reference

3 August 2017

L A Chantrill

1 reference

3 August 2017

J S Samra

1 reference

3 August 2017

A J Gill

1 reference

3 August 2017

J G Kench

1 reference

3 August 2017

N D Merrett

1 reference

3 August 2017

A Das

1 reference

3 August 2017

E A Musgrove

1 reference

3 August 2017

R L Sutherland

1 reference

3 August 2017

A V Biankin

1 reference

3 August 2017

NSW Pancreatic Cancer Network

1 reference

3 August 2017

language of work or name

1 reference

11 January 2012

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

1 reference

3 August 2017

page(s)

1713-1722

1 reference

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Margin clearance and outcome in resected pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

ABH and Lewis histo-blood group antigens in cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Specific Antigen in Serum of Patients with Colon Carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Colorectal carcinoma antigens detected by hybridoma antibodies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Utility of tumor markers in determining resectability of pancreatic cancer.

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

Clinical usefulness of CA-19-9 in pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR561

Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3387824

Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9

26 October 2018

1 reference

12 December 2020

Prognostic value of CA 19-9 serum course in pancreatic cancer

1 reference

12 December 2020

Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population

1 reference

12 December 2020

Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDR561

1 reference

3 August 2017

1 reference

3 August 2017

1 reference